ALX Oncology Announced Earlier Sunday, Combination Of Evorpacept Plus Rituximab And Lenalidomide Generated Complete Responses In 92% Of Patients With Untreated Indolent Non-Hodgkin Lymphoma Comparing Favorably To ~50% Historical CR Rate For R2 Alone

Benzinga · 1d ago

ALX Oncology Holdings Inc., ("ALX Oncology" or the "Company") (NASDAQ:ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that positive data from a Phase 2 investigator-sponsored trial (IST) of evorpacept, in combination with standard-of-care rituximab and lenalidomide, for patients with indolent B-cell non-Hodgkin lymphoma (iNHL) is being presented Sunday, December 7 during a poster presentation at the American Society of Hematology (ASH) Annual Meeting 2025 in Orlando, Florida.